- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
LG Debuts 5MP High-Definition Mammography Monitor
Intended for mammography and digital breast tomosynthesis (DBT) interpretation, the device reportedly emphasizes high-definition image quality and ease of use for radiologists.
Offering enhanced visualization of mammography and other breast imaging, LG has launched the 21HQ613D-B diagnostic monitor, which allow for high-definition views on a 21.3-inch, 5-megapixel (MP) platform.
Emphasizing the image quality of the 21HQ613D-B device, LG noted the monitor, which received FDA clearance in February 2024, gives radiologists 2,048 x 2,560 resolution, 1,100 cd/m2 luminance and an 1800:1 contrast ratio.
Cleared by the FDA in February 2024, the newly launched 21HQ613D-B diagnostic monitor offers radiologists 2,048 x 2,560 resolution, 1,100 cd/m2 luminance and an 1800:1 contrast ratio, according to LG, the manufacturer of the device. (Image courtesy of LG.)
While the 21HQ613D-B diagnostic monitor is intended for the assessment of digital mammography and digital breast tomosynthesis (DBT), LG noted that radiologists can also utilize the monitor for review of breast magnetic resonance imaging (MRI), computed tomography (CT) or ultrasound images.
The 21HQ613D-B diagnostic monitor also has a Focus View Mode, which allows radiologists to highlight a key part of an image, and a Multi-Resolution Mode, which facilitates resolution adjustments to optimize viewing of different images, according to LG.
"LG's new 5MP diagnostic monitor is tailored for reviewing mammograms and breast tomosynthesis, providing a high-quality medical imaging display with both simple management and practical features for users,” said Stephen K. Hu, the head of medical displays for LG Business Solutions USA. “We’re dedicated to providing cutting-edge solutions for the medical sector with our display technologies, and the addition of the latest 5MP monitor underscores this commitment to innovation.”
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
